Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity...